drugset / Trial / NCT06636162
Window of Opportunity Study of DSP-0390 in Gliomas
Phase 0
Recruiting
20 enrolled
Washington University School of Medicine
Sumitomo Pharma America, Inc. · collabThe Foundation for Barnes-Jewish Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. The hypothesis is that DSP-0390 will accumulate in brain tumor tissue at pharmacologically relevant concentrations, and that alterations in cholesterol metabolism driven by mutant IDH will increase susceptibility to DSP-0390 and lead to tumor cell death.
Timeline
- Start
- 2025-04-03
- Primary completion
- 2027-04-17
- Completion
- 2027-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DSP-0390 | Small molecule | 120 mg | Oral |
| Subject | DSP-0390 | Small molecule | 180 mg | Oral |